Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
EYPT

EYPT - EyePoint Pharmaceuticals Inc Stock Price, Fair Value and News

11.11USD-0.36 (-3.14%)Market Closed

Market Summary

EYPT
USD11.11-0.36
Market Closed
-3.14%

EYPT Alerts

  • 1 major insider buys and 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

EYPT Stock Price

View Fullscreen

EYPT RSI Chart

EYPT Valuation

Market Cap

597.4M

Price/Earnings (Trailing)

-7.57

Price/Sales (Trailing)

11.94

EV/EBITDA

-4.68

Price/Free Cashflow

-35.87

EYPT Price/Sales (Trailing)

EYPT Profitability

EBT Margin

-141.37%

Return on Equity

-31.57%

Return on Assets

-23.97%

Free Cashflow Yield

-2.79%

EYPT Fundamentals

EYPT Revenue

Revenue (TTM)

50.0M

Rev. Growth (Yr)

52.08%

Rev. Growth (Qtr)

-16.71%

EYPT Earnings

Earnings (TTM)

-78.9M

Earnings Growth (Yr)

-38.37%

Earnings Growth (Qtr)

-107.7%

Breaking Down EYPT Revenue

Last 7 days

-11.4%

Last 30 days

-32.3%

Last 90 days

-56.0%

Trailing 12 Months

71.5%

How does EYPT drawdown profile look like?

EYPT Financial Health

Current Ratio

5.08

EYPT Investor Care

Shares Dilution (1Y)

51.84%

Diluted EPS (TTM)

-1.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202450.0M000
202339.8M37.3M42.5M46.0M
202238.9M41.5M42.4M41.4M
202134.3M39.2M32.5M36.9M
202025.8M22.8M35.9M34.4M
20195.7M12.2M14.2M20.4M
20182.9M3.0M3.1M4.6M
20176.1M7.5M7.6M2.6M
20167.9M1.6M3.1M4.6M
201526.4M26.6M20.3M14.1M
20143.7M3.5M28.2M28.1M
20132.4M2.1M2.2M2.2M
20126.5M3.5M2.4M2.4M
20119.5M5.0M6.1M6.4M
2010023.1M18.5M14.0M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of EyePoint Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 14, 2024
guyer david r
acquired
32,646
3.3398
9,775
-
May 14, 2024
guyer david r
sold
-147,045
12.649
-11,625
-
May 06, 2024
cormorant asset management, lp
bought
10,081,700
11.8608
850,000
-
Apr 18, 2024
cormorant asset management, lp
bought
10,489,400
18.0304
581,765
-
Mar 30, 2024
paggiarino dario a.
sold (taxes)
-528,036
20.67
-25,546
chief medical officer
Mar 30, 2024
paggiarino dario a.
acquired
-
-
50,404
chief medical officer
Feb 27, 2024
duker jay s.
gifted
-
-
2,500
president and ceo
Feb 27, 2024
duker jay s.
gifted
-
-
-2,500
president and ceo

1–10 of 50

Which funds bought or sold EYPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
129
100,153
194,153
0.03%
May 20, 2024
Virtu Financial LLC
new
-
241,000
241,000
0.02%
May 17, 2024
Ikarian Capital, LLC
reduced
-99.72
-8,485,840
21,642
-%
May 16, 2024
JANE STREET GROUP, LLC
added
207
2,822,450
4,437,720
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
884
792,879
894,494
-%
May 16, 2024
COMERICA BANK
added
150
13,410
24,202
-%
May 15, 2024
ALGERT GLOBAL LLC
new
-
429,000
429,000
0.02%
May 15, 2024
Voya Investment Management LLC
added
209
447,691
700,445
-%
May 15, 2024
Cormorant Asset Management, LP
added
14.16
2,939,560
142,483,000
6.25%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
added
81.32
16,217,000
42,299,900
0.02%

1–10 of 40

Are Funds Buying or Selling EYPT?

Are funds buying EYPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EYPT
No. of Funds

Unveiling EyePoint Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 01, 2024
adage capital management, l.p.
9.90%
5,156,299
SC 13G/A
Apr 30, 2024
adage capital management, l.p.
10.35%
5,156,299
SC 13G
Feb 14, 2024
price t rowe associates inc /md/
5.6%
2,522,704
SC 13G
Feb 14, 2024
ra capital management, l.p.
6.1%
3,095,136
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
9.99%
4,774,389
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
9.15%
4,466,420
SC 13G/A
Feb 06, 2024
franklin resources inc
9.5%
4,640,651
SC 13G/A
Dec 14, 2023
cormorant asset management, lp
12.36%
6,038,235
SC 13G/A
Dec 08, 2023
ew healthcare partners, l.p.
4.8%
2,247,432
SC 13D/A
Sep 11, 2023
franklin resources inc
11.8%
4,130,137
SC 13G/A

Recent SEC filings of EyePoint Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
May 16, 2024
4
Insider Trading
May 14, 2024
144
Notice of Insider Sale Intent
May 09, 2024
10-Q
Quarterly Report
May 08, 2024
4
Insider Trading
May 08, 2024
8-K
Current Report
May 06, 2024
8-K
Current Report
May 01, 2024
SC 13G/A
Major Ownership Report
Apr 30, 2024
SC 13G
Major Ownership Report
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
DEFA14A
DEFA14A

Peers (Alternatives to EyePoint Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

EyePoint Pharmaceuticals Inc News

Latest updates
Yahoo New Zealand News20 May 202406:02 am

EyePoint Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-16.7%11,684,00014,028,00015,202,0009,105,0007,683,00010,533,00010,012,00011,565,0009,294,00011,544,0009,059,0009,013,0007,323,0007,131,00015,695,0004,122,0007,489,0008,634,0002,509,0007,210,0002,012,000
Operating Expenses-100.0%-30,382,00029,600,00031,866,00029,237,00054,270,00028,410,00030,781,00027,578,00029,593,50024,372,00019,992,00018,258,00019,868,00017,652,00015,274,00018,933,00017,618,50016,569,00017,375,00016,663,000
  S&GA Expenses-96.8%6,000185,000479,0005,288,0005,737,0005,915,0006,016,0006,883,0006,693,0007,811,0007,374,0006,659,0005,659,0005,810,0005,269,0006,089,0008,125,0007,399,0007,778,0007,284,0007,311,000
  R&D Expenses67.9%30,139,00017,951,00017,363,00015,730,00013,618,00015,543,00011,162,00012,992,0009,945,0008,918,0008,498,0005,605,0005,479,0005,205,0004,090,0003,276,0004,853,0004,131,5003,484,0003,955,0003,797,000
EBITDA Margin6.9%-1.40-1.50-2.35-2.65-2.49-2.38-1.16-1.17-1.22-1.28-1.44-1.19---------
Interest Expenses----435,000812,000781,000662,000552,0001,194,0001,388,0001,388,0001,376,0001,346,0001,827,0001,840,0001,806,0001,784,0001,787,0001,770,0001,599,0001,020,000
EBT Margin8.0%-1.41-1.54-2.40-2.74-2.57-2.47-1.25-1.28-1.37-1.44-1.63-1.36---------
Net Income-107.7%-29,284,000-14,099,000-12,612,000-22,920,000-21,164,000-43,452,000-18,420,000-19,406,000-20,976,000-19,432,000-16,695,000-10,010,000-12,280,000-15,469,000-3,801,000-12,950,000-13,174,000-10,410,000-15,647,000-11,498,000-19,238,000
Net Income Margin-2.6%-1.58-1.54-2.36-2.84-2.57-2.47-1.84-1.85-1.72-1.58-1.67-1.06---------
Free Cashflow-34.9%-32,365,000-23,992,000-16,924,00056,627,000-17,319,000-13,173,000-14,334,000-19,341,000-20,307,000-16,668,000-7,918,000-10,568,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.3%32935516017615518022023324526316817918792.0077.0070.0080.0073.0079.0091.0082.00
  Current Assets-7.9%31834515016714617319220622023814215215963.0048.0040.0050.0042.0047.0059.0048.00
    Cash Equivalents-3.6%27128113314010696.0075.0082.0010217912012813945.0029.0023.0026.0022.0032.0044.0044.00
  Inventory9.0%4.004.005.004.004.003.004.003.003.004.005.005.006.005.004.004.003.002.003.002.001.00
  Net PPE27.2%7.005.004.003.003.001.001.001.001.000.001.001.001.001.000.000.000.000.000.000.000.00
Liabilities-10.7%79.0089.0010111876.0084.0084.0082.0078.0079.0076.0072.0071.0073.0069.0065.0064.0065.0063.0063.0062.00
  Current Liabilities-1.1%63.0063.0064.0069.0027.0035.0034.0033.0032.0024.0020.0016.0013.0015.0013.0010.0010.0012.0010.0011.0025.00
  Short Term Borrowings-----5.0010.0010.0010.0010.00------------
  Long Term Debt-----29.0029.0029.0029.0029.0037.0036.0036.0038.0038.0051.0050.0048.0047.0047.0046.0032.00
    LT Debt, Non Current-----29.0029.0029.0029.0029.0037.0036.0036.0038.0038.0051.0050.0048.0047.0047.0046.0032.00
Shareholder's Equity-6.2%25026659.0057.0078.0096.0013615116718493.0010711619.008.004.0016.008.0016.0028.0020.00
  Retained Earnings-3.9%-771-742-728-715-692-671-627-609-590-569-549-532-522-510-495-491-478-465-454-439-427
  Additional Paid-In Capital1.3%1,0201,008786772770767764760756753642639638528502495494473470466447
Shares Outstanding1.7%50.0049.0035.0034.0034.0034.0037.0037.0037.0034.0027.0029.00---------
Float----233---210---192---62.00---101-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-34.9%-31,171-23,109-15,20457,023-16,835-12,588-13,136-19,123-20,158-16,668-7,787-10,543-15,0995,8951,136-5,121-16,345-11,486-14,772-17,107-13,334
  Share Based Compensation253.7%12,6993,5903,6291,7883,0503,3613,1994,1403,4772,8082,4711,1809881,2632,3897351,1608579771,4961,238
Cashflow From Investing144.1%20,806-47,148-1,72013,46732,08632,9176,272-12.00-56,442-32,965-131-25.00--192-128-26.00-16.00-6.00--25.00-182
Cashflow From Financing-99.9%115218,48510,362-36,658-5,119-58.0092.00-276-448108,516-2.00-381108,76910,4804,9041,66220,4461,9452,37117,91411,634
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EYPT Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 11,684$ 7,683
Operating expenses:  
Cost of sales759640
Research and development30,13913,618
Sales and marketing65,737
General and administrative14,1019,242
Total operating expenses45,00529,237
Loss from operations(33,321)(21,554)
Other (expense) income:  
Interest and other income, net4,0371,202
Interest expense0(812)
Total other (expense) income, net4,037390
Net loss$ (29,284)$ (21,164)
Net loss per share - basic$ (0.55)$ (0.56)
Net loss per share - diluted$ (0.55)$ (0.56)
Weighted average shares outstanding - basic52,91337,486
Weighted average shares outstanding - diluted52,91337,486
Net Income (Loss)$ (29,284)$ (21,164)
Other comprehensive loss:  
Unrealized (loss) gain on available-for-sale securities, net of tax of $0 for periods presented(28)57
Comprehensive loss(29,312)(21,107)
Product [Member]  
Revenues:  
Total revenues6587,394
License and Collaboration Agreements [Member]  
Revenues:  
Total revenues10,56334
Royalty Income [Member]  
Revenues:  
Total revenues$ 463$ 255

EYPT Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 271,013$ 281,263
Marketable securities28,33549,787
Accounts and other receivables, net3,015805
Prepaid expenses and other current assets11,0899,039
Inventory4,2573,906
Total current assets317,709344,800
Property and equipment, net6,6775,251
Operating lease right-of-use assets4,7114,983
Restricted cash150150
Total assets329,247355,184
Current liabilities:  
Accounts payable7,0826,504
Accrued expenses15,94017,521
Deferred revenue38,37738,592
Other current liabilities1,181646
Total current liabilities62,58063,263
Deferred revenue - noncurrent12,10920,692
Operating lease liabilities - noncurrent4,6244,906
Total liabilities79,31388,861
Contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding00
Common stock, $.001 par value, 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 49,885,701 and 49,043,074 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively5049
Additional paid-in capital1,020,4781,007,556
Accumulated deficit(771,430)(742,146)
Accumulated other comprehensive income836864
Total stockholders' equity249,934266,323
Total liabilities and stockholders' equity$ 329,247$ 355,184
EYPT
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEhttps://eyepointpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES144

EyePoint Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for EyePoint Pharmaceuticals Inc? What does EYPT stand for in stocks?

EYPT is the stock ticker symbol of EyePoint Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of EyePoint Pharmaceuticals Inc (EYPT)?

As of Wed May 22 2024, market cap of EyePoint Pharmaceuticals Inc is 597.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYPT stock?

You can check EYPT's fair value in chart for subscribers.

What is the fair value of EYPT stock?

You can check EYPT's fair value in chart for subscribers. The fair value of EyePoint Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of EyePoint Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EYPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is EyePoint Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether EYPT is over valued or under valued. Whether EyePoint Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact EyePoint Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYPT.

What is EyePoint Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, EYPT's PE ratio (Price to Earnings) is -7.57 and Price to Sales (PS) ratio is 11.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on EyePoint Pharmaceuticals Inc's stock?

In the past 10 years, EyePoint Pharmaceuticals Inc has provided -0.11 (multiply by 100 for percentage) rate of return.